ZOMEDICA CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1421 USD | +1.86% |
|
+8.23% | -29.02% |
| 04-01 | Zomedica Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 04-01 | Zomedica Seeks Acquisitions | CI |
| Sales 2022 | 18.93 1.52K | Sales 2023 | 25.19 2.02K | Capitalization | 196M 15.72B |
|---|---|---|---|---|---|
| Net income 2022 | -17M -1.36B | Net income 2023 | -34M -2.72B | EV / Sales 2022 | 2,449,963 x |
| Net cash position 2022 | 113M 9.08B | Net cash position 2023 | 87.77M 7.03B | EV / Sales 2023 | 4,304,730 x |
| P/E ratio 2022 |
-9.39
x | P/E ratio 2023 |
-5.68
x | Employees | 144 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98.41% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zomedica Corp.
More press releases
| 1 day | +1.86% | ||
| 1 week | +8.23% | ||
| 1 month | -2.60% | ||
| 3 months | +6.12% | ||
| 6 months | -15.42% | ||
| Current year | -29.02% |
1 week
0.13
0.15
1 month
0.120.15
Current year
0.120.20
1 year
0.120.25
3 years
0.121.07
5 years
0.062.91
10 years
0.062.98
| Managers | Title | Age | Since |
|---|---|---|---|
Larry Heaton
CEO | Chief Executive Officer | 67 | 30/09/21 |
Peter Donato
DFI | Director of Finance/CFO | 53 | 15/03/23 |
Evan Saint Peter
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Larry Heaton
CEO | Chief Executive Officer | 67 | 30/09/21 |
Johnny Powers
BRD | Director/Board Member | 62 | 15/08/19 |
Robert Cohen
BRD | Director/Board Member | 66 | 15/06/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 0.1421 | +1.86% | 10,595,336 |
| 29/04/24 | 0.1395 | +4.89% | 4,555,356 |
| 26/04/24 | 0.133 | +2.23% | 2,709,691 |
| 25/04/24 | 0.1301 | -0.08% | 1,376,380 |
| 24/04/24 | 0.1302 | -0.84% | 2,571,159 |
Delayed Quote Nyse, April 30, 2024 at 09:00 pm
More quotes
Zomedica Corp. is a veterinary health company. The Company is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The Company's product portfolio includes diagnostics and medical devices that emphasize patient health and practice health. Its Diagnostics segment consists of TRUFORMA, VetGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field (tPEMF) therapy.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.02% | 137M | |
| -41.83% | 862M |
- Stock Market
- Equities
- ZOM Stock
